DOSEGUY

DNSP-11

guinea pig

Also seen as: dopamine neuron stimulating peptide-11, DNSP11, DNSP 11

The Dose Guy’s verdict
Sep 1, 2026
3 sources

Interesting mechanism, wrong stage. DNSP-11 has moved from cells to rats to macaques without cutting corners, and the macaque data is genuinely encouraging. But no human has ever been dosed, and that means no dosing, safety, or outcome data exists. If the Parkinson’s story moves to a trial, this gets interesting fast. Until then, there’s nothing to run.

Would I take it?Not yet. Good animal work, nobody's been the first human.

What it is

DNSP-11 is an 11-amino-acid peptide derived from the prodomain of GDNF, the growth factor the brain uses to keep dopamine neurons alive. Where GDNF itself is too large to deliver easily, DNSP-11 is small enough to reach the brain through the nose in animal work. It sits on the nootropic shelf next to compounds like dihexa, but the story here is narrower and more honest: this is a Parkinson’s-model tool, not a general cognition booster, and the research group behind it has been methodical about moving from dish to rodent to primate without skipping steps.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Animal-only, but the animal work is unusually careful for this shelf:

One injection into the substantia nigra of normal adult rats increased resting dopamine and dopamine metabolite levels for up to 28 days.PLOS One 2010 · cells + rats
Intranasal DNSP-11 reached the striatum and substantia nigra within 30 minutes, and repeated dosing at 300 micrograms for three weeks increased dopamine turnover in both regions.J Neurosci Methods 2015 · rats
Ten weeks of repeated intranasal dose escalation in Rhesus macaques produced bilateral striatal target engagement, with no observable adverse behavioral effects or weight loss.J Neurosci Methods 2018 · macaques
No human administration study or clinical trial of DNSP-11 exists.as of Aug 2026

Realistic protocols

I’m not building a protocol from animal dosing that has never touched a human. The animal studies dosed DNSP-11 intranasally, and the few self-experimenters follow that route, typically at low microgram doses once or twice daily for a few weeks at a time. That protocol is extrapolation, not evidence. If you’re drawn to the dopamine-neurotrophic angle, dihexa has more community mileage, though it carries its own caveats. If you run DNSP-11 anyway, go low, go short, and log everything you notice. Nobody has measured what this does to a person, let alone what dose is right.

Side effects

No human safety data exists. Everything here is community anecdote:

anecdotalMild nasal irritation from intranasal dosing, consistent with the delivery route.
anecdotalSubtle motivation or mood shifts reported by some users, hard to separate from expectation.
unknownA neurotrophic peptide with zero human safety data. The macaque work looked clean, but clean in a primate model is not studied in a person.

Where to buy

No live listings from tracked vendors right now.